ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NCEL / options
KPTI (29) CTXR (40) RADX (46) ALLR (32) ⌘ Pro Terminal →

NewcelX Ltd. (NCEL) Options Positioning, Max Pain & Unusual Sweeps

$2.49 -2.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.47

NewcelX Ltd. (NCEL) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $14.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NCEL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, NewcelX Ltd. (NASDAQ: NCEL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $2.49 (-2.35% 1D, market cap $14.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NCEL ranks #870 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NCEL compare to KPTI and CTXR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NCEL carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KPTI (Karyopharm Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $15.0M) and CTXR (Citius Pharmaceuticals Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $14.4M). Among the 5-stock peer group, NCEL leads on earnings multiple (N/A) while NCEL leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NCEL?
▼

Per NCEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001783036), NewcelX Ltd. generated $7.2M in revenue (+24.0% YoY), -$8.3M in net income, and -$2.8M in free cash flow against $11.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.47 (-0.61%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510028
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (5)Whales (3)SEC (10)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.7% Base Target
$7 Bull$2 Base$2 Bear
📬 FREE NCEL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NCEL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY NCEL SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (36% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (25% of score)

FRED Regime × Technicals: 14% of 52W Range • RSI-14 at 43.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$2.84-8.1% Next Q
Q2 (-2Q)
33
Grade E$2.61+5% Next Q
Q3 (-1Q)
31
Grade E$2.74-9.1% Next Q
Current
28
Grade E$2.49-10% Hist 90D α
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NCEL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NCEL currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.00) and Max Pain ($2.61) forces dealer call-delta covering toward $6.80.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NCEL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NCEL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (NCEL)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for NCEL.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NCEL)

  • ✓Walkthrough of NCEL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NCEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.13%▼ DESCENDING CHANNEL
2026-11-03O $2.69H $2.69L $2.49C $2.49VOL 11.2K
RES: $3.14SUP: $2.17SMA50: $3.00SMA200: $3.10
$9.75$7.75$5.75$3.74$1.74RES $3.14SUP $2.17$2.492026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NCEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NCEL Butterfly Map → + Track NCEL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +24.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NCEL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NCEL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NCEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NCEL)

Health Care Rank #870 of 1015 ⚔️ KPTI vs NCEL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NCEL vs. KPTI, CTXR, RADX, ALLR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, NewcelX Ltd. (NCEL) ranks #870 by composite RQD confidence (28/100, grade E) and #856 by equity capitalization ($14.7M). Within this direct 5-issuer industry benchmark cohort, NCEL leads on earnings valuation at N/A trailing P/E, while NCEL leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RADX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with NCEL at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NCEL ACTIVE
NewcelX Ltd.
E 28/100 — — -35.0% -2.35% $14.7M Benchmark Subject
KPTI
Karyopharm Therapeutics Inc.
E 29/100 — — -35.0% -83.08% $15.0M /kpti-vs-ncel →
CTXR
Citius Pharmaceuticals Inc.
D- 40/100 — — -35.0% +7.44% $14.4M /ctxr-vs-ncel →
RADX
Radiopharm Theranostics Limited
D 46/100 — — — -8.05% $15.6M /radx-vs-ncel →
ALLR
Allarity Therapeutics Inc.
E 32/100 — — -35.0% +12.33% $13.8M /allr-vs-ncel →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001783036 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NewcelX Ltd. (NCEL) reported GAAP revenue of $7.2M (+24.0% vs. FY2024 revenue of $5.8M , and -15.0% cumulative change since FY2023) , GAAP net income of -$8.3M, operating cash flow of -$2.8M, and free cash flow of -$2.8M (-158.8% YoY). On the balance sheet, NCEL closed FY2025 with $11.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $7.2M -$8.3M -$2.8M -$2.8M $11.4M —
FY2024 (FY) 2024-12-31 $5.8M -$7.2M -$1.1M -$1.1M $903.0K —
FY2023 (FY) 2023-12-31 $8.4M -$3.3M -$3.4M -$3.4M — —

3. NCEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, NewcelX Ltd. (NASDAQ: NCEL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $2.49 (-2.35% 1D, market cap $14.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NCEL ranks #870 in composite RQD confidence.

How does NCEL compare to KPTI and CTXR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NCEL carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KPTI (Karyopharm Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $15.0M) and CTXR (Citius Pharmaceuticals Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $14.4M). Among the 5-stock peer group, NCEL leads on earnings multiple (N/A) while NCEL leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NCEL?

Per NCEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001783036), NewcelX Ltd. generated $7.2M in revenue (+24.0% YoY), -$8.3M in net income, and -$2.8M in free cash flow against $11.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NCEL trading relative to its 50-day, 200-day, and 52-week technical levels?

NCEL last traded at $2.49 (-2.35% on volume of 11,170 shares), positioning the stock -17.00% below its 50-day simple moving average ($3.00) and -19.68% below its 200-day simple moving average ($3.10). Across its 52-week range of $1.83 to $6.48, NCEL sits at the 14.2% percentile with a 14-day RSI of 43.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.18 to $2.80).

Direct Sub-Reports: NCEL RQD Cockpit NCEL 12M Forecast NCEL Earnings & Move NCEL Dividends & DRIP NCEL Insiders & 13F NCEL Whale Options NCEL Profit Sankey NCEL News & Why
ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ SEC XBRL & RQD VERIFIED

NCEL — NewcelX Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

NewcelX Ltd. (NCEL) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.49 (-2.35% 1D, market capitalization $14.7M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -17.84%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

NewcelX Ltd. (NCEL) is a NASDAQ-listed operating company in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity market capitalization of $14.7M. The business operates with a gross margin of 0%, an operating margin of 0%, and a return on invested capital (ROIC) of -35% (free cash flow yield of -17.84%). Within the Biotechnology: Pharmaceutical Preparations peer group, investor evaluation centers on operating leverage, unit margin durability, and capital allocation efficiency across market cycles.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), NewcelX Ltd. (NCEL) reported $7.2M in annual revenue (up from $5.8M in FY2024, +24.0% YoY) and -$8.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($8.4M revenue, -$3.3M net income) through FY2025, NCEL scaled operating cash flow to -$2.8M and free cash flow to -$2.8M, backed by $11.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -17.84% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.83 – $6.48 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not establish upstream or downstream dependencies, sector correlations beyond the stated beta of 1.0, or second-order bottlenecks. A prospective investor should note that the absence of mapped links is itself a data limitation rather than evidence of independence.

  • Key Question #1: Can NCEL sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $7.2M and free cash flow of -$2.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NCEL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NCEL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NewcelX Ltd. (NCEL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NCEL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NCEL Bull vs. Bear Conversation Board — What's Your Call at $2.49?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NCEL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NCEL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $3.06 (+20.0%)
📌 Pinned Debate

Price sits near the low end of its 52-week range at $2.69 against a $1.83 low, with beta of 1.0 and a $2.2M cash balance in FY 2025.

Long NCEL at $2.55 targeting $3.06. Price sits near the low end of its 52-week range at $2.69 against a $1.83 low, with beta of 1.0 and a $2.2M cash balance in FY 2025.. Institutional whale score is 3/20 and the risk/reward vs. the $1.83 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@RedlineAuditor Shorting a 3/20 institutional whale-flow stock at $2.55 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $1.94 (-23.9%)
Spot @ $2.55

Reported revenue is $0.0M across three fiscal years while net losses of -$8.3M in FY 2025 and a ROIC of -35% show persistent cash consu

Fading this rally in NCEL at $2.55. Reported revenue is $0.0M across three fiscal years while net losses of -$8.3M in FY 2025 and a ROIC of -35% show persistent cash consumption.. With a beta of 1.0 and the stock sitting at $2.55 (52-wk range $1.83–$6.48), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%